Early clinical factors predicting the development of critical disease in Japanese patients with COVID-19: A single-center, retrospective, observational study.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
04 2021
Historique:
received: 20 07 2020
revised: 09 09 2020
accepted: 11 10 2020
pubmed: 23 10 2020
medline: 6 3 2021
entrez: 22 10 2020
Statut: ppublish

Résumé

The factors predicting the progression of coronavirus disease-2019 (COVID-19) from mild to moderate to critical are unclear. We retrospectively evaluated risk factors for disease progression in Japanese patients with COVID-19. Seventy-four patients with laboratory-confirmed COVID-19 were hospitalized in our hospital between February 20, 2020, and June 10, 2020. We excluded asymptomatic, non-Japanese, and pediatric patients. We divided patients into the stable group and the progression group (PG; requiring mechanical ventilation). We compared the clinical factors. We established the cutoff values (COVs) for significantly different factors via receiver operating characteristic curve analysis and identified risk factors by univariate regression. We enrolled 57 patients with COVID-19 (median age 52 years, 56.1% male). The median time from symptom onset to admission was 8 days. Seven patients developed critical disease (PG: 12.2%), two (3.5%) of whom died; 50 had stable disease. Univariate logistic analysis identified an elevated lactate dehydrogenase (LDH) level (COV: 309 U/l), a decreased estimated glomerular filtration rate (eGFR; COV: 68 ml/min), lymphocytopenia (COV: 980/μl), and statin use as significantly associated with disease progression. However, in the Cox proportional hazards analysis, lymphocytopenia at admission was not significant. We identified three candidate risk factors for progression to critical COVID-19 in adult Japanese patients: statin use, elevated LDH level, and decreased eGFR.

Identifiants

pubmed: 33090527
doi: 10.1002/jmv.26599
pmc: PMC7675319
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2141-2148

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

MMWR Morb Mortal Wkly Rep. 2020 Feb 07;69(5):140-146
pubmed: 32027631
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2021 Apr;93(4):2141-2148
pubmed: 33090527
J Infect Dis. 2012 Jan 1;205(1):13-9
pubmed: 22170954
Open Forum Infect Dis. 2015 Mar 20;2(1):ofv028
pubmed: 26034777
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Circulation. 2013 Jan 15;127(2):251-7
pubmed: 23319813
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Kidney Int. 2003 Jan;63(1):12-23
pubmed: 12472764
Clin Microbiol Infect. 2020 Sep;26(9):1242-1247
pubmed: 32526275

Auteurs

Takatoshi Higuchi (T)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Tsutomu Nishida (T)

Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Hiromi Iwahashi (H)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Osamu Morimura (O)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Yasushi Otani (Y)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Yukiyoshi Okauchi (Y)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Masaru Yokoe (M)

Department of Neurology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Norihiro Suzuki (N)

Infection Control Office, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Masami Inada (M)

Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Kinya Abe (K)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.
Infection Control Office, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH